Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies
The most practical screening test for hepatitis C virus antibodies are second and third-generation enzyme immunoassays. We evaluated the usefulness of the third generation microparticle enzyme immunoassay (MEIA) in predicting HCV viraemia in anti-HCV positive patients. Serum samples from 106 patient...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2002-10-01
|
| Series: | Annals of Hepatology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119321635 |
| _version_ | 1818643218619695104 |
|---|---|
| author | Silvia Sookoian, MD Gustavo Castaño, MD |
| author_facet | Silvia Sookoian, MD Gustavo Castaño, MD |
| author_sort | Silvia Sookoian, MD |
| collection | DOAJ |
| description | The most practical screening test for hepatitis C virus antibodies are second and third-generation enzyme immunoassays. We evaluated the usefulness of the third generation microparticle enzyme immunoassay (MEIA) in predicting HCV viraemia in anti-HCV positive patients. Serum samples from 106 patients with positive anti-HCV were obtained. To evaluate the diagnostic value of the MEIA test in predicting HCV viraemia, anti-HCV positive patients were categorized in two groups according to the presence or absence of serum HCV-RNA. Among the 106 patients, 26 had non detectable serum HCV-RNA and 80 had detectable HCV-RNA by PCR. The assay automatically calculates a result based on the ratio of sample rate to the cut-of rate for each sample and control (S/CO). When the means of S/CO values for patients with detectable and non detectable HCV-RNA were analyzed, a statistically significant difference was found, (79.3 SD 22.2 vs. 8.2 SD 6.4, respectively) (p 0.0001). We further analyzed the best cut-off value of the S/CO in differentiating viremic from non viremic patients. The S/CO value of 26 showed a sensitivity of 99% and a specificity off 96% in discriminating both categories of HCV infected patients. In conclusion, our data demonstrate that viremic HCV patients had higher S/CO values in the MEIA test in comparison with non viremic patients. Hence, this assay may be used to predict HCV viraemia in anti-HCV positive individuals. |
| first_indexed | 2024-12-16T23:55:28Z |
| format | Article |
| id | doaj.art-70656aee01a34d3a9bbbacf5ec1b24a8 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-12-16T23:55:28Z |
| publishDate | 2002-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-70656aee01a34d3a9bbbacf5ec1b24a82022-12-21T22:11:13ZengElsevierAnnals of Hepatology1665-26812002-10-0114179182Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodiesSilvia Sookoian, MD0Gustavo Castaño, MD1Unidad de Hepatología, Departamento de Medicina Interna, Hospital Dr. Cosme Argerich; Address for correspondence:Unidad de Hepatología, Departamento de Medicina Interna, Hospital Dr. Cosme ArgerichThe most practical screening test for hepatitis C virus antibodies are second and third-generation enzyme immunoassays. We evaluated the usefulness of the third generation microparticle enzyme immunoassay (MEIA) in predicting HCV viraemia in anti-HCV positive patients. Serum samples from 106 patients with positive anti-HCV were obtained. To evaluate the diagnostic value of the MEIA test in predicting HCV viraemia, anti-HCV positive patients were categorized in two groups according to the presence or absence of serum HCV-RNA. Among the 106 patients, 26 had non detectable serum HCV-RNA and 80 had detectable HCV-RNA by PCR. The assay automatically calculates a result based on the ratio of sample rate to the cut-of rate for each sample and control (S/CO). When the means of S/CO values for patients with detectable and non detectable HCV-RNA were analyzed, a statistically significant difference was found, (79.3 SD 22.2 vs. 8.2 SD 6.4, respectively) (p 0.0001). We further analyzed the best cut-off value of the S/CO in differentiating viremic from non viremic patients. The S/CO value of 26 showed a sensitivity of 99% and a specificity off 96% in discriminating both categories of HCV infected patients. In conclusion, our data demonstrate that viremic HCV patients had higher S/CO values in the MEIA test in comparison with non viremic patients. Hence, this assay may be used to predict HCV viraemia in anti-HCV positive individuals.http://www.sciencedirect.com/science/article/pii/S1665268119321635Anti-HCVMEIAHCV-RNAmicroparticle enzyme immunoassaydiagnostic applicationAxSYM |
| spellingShingle | Silvia Sookoian, MD Gustavo Castaño, MD Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies Annals of Hepatology Anti-HCV MEIA HCV-RNA microparticle enzyme immunoassay diagnostic application AxSYM |
| title | Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies |
| title_full | Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies |
| title_fullStr | Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies |
| title_full_unstemmed | Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies |
| title_short | Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies |
| title_sort | evaluation of a third generation anti hcv assay in predicting viremia in patients with positive hcv antibodies |
| topic | Anti-HCV MEIA HCV-RNA microparticle enzyme immunoassay diagnostic application AxSYM |
| url | http://www.sciencedirect.com/science/article/pii/S1665268119321635 |
| work_keys_str_mv | AT silviasookoianmd evaluationofathirdgenerationantihcvassayinpredictingviremiainpatientswithpositivehcvantibodies AT gustavocastanomd evaluationofathirdgenerationantihcvassayinpredictingviremiainpatientswithpositivehcvantibodies |